You say there doesn't seem to be any big pharma interest. Based on a statement made in the last report I would say an 80% success rate winning contracts would indicate definite interest. Short position is currently declining and institutional ownership is increasing... this will start to leg up.
Keith Murphy, chairman and chief executive officer of Organovo, commented on the results, "Organovo has had a successful launch of its exVive3D™ Human Liver Tissue, and customer response continues to be strong. Our contracted customers include companies from among the top 25 global pharma companies, smaller public pharma companies, and private venture-backed pharma companies. Conversion of potential customers, those requesting quotes, to signed contracts has been high, with a win rate over 80% to date. We are encouraged that we have a high win rate, that our commercial pricing continues to be supported, and that we have received repeat business."
News 
Market Data 
Discover 
AI
